EUVIMEDEUVIMED entdecken
Open Access · CC BY-SA 4.0

CRISPR-CAS THERAPEUTICS AGAINST EXTENSIVELY DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS: OPPORTUNITIES FOR PRECISION ANTIMICROBIAL INTERVENTION

Muqadas Munir, Asma BiBi, Wajid Ullah, Dr. Minahil Malik, Dr. Nazia Akber Mir, Sidra Qureshi, Maria Fareed Siddiqui, Maham Rafique, Waneeza Ahmed

Genetics and Molecular Research · 07.07.2026

DOI: 10.4238/fsb1e572 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genetics and Molecular Research, online erschienen am 07.07.2026. Verfasst von Muqadas Munir und 8 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Extensively drug-resistant tuberculosis (XDR-TB) remains a critical global health threat, largely due to the toxicity, prolonged treatment durations, and severe dysbiosis associated with conventional broad-spectrum antibiotic regimens. To address this, we evaluated the in vitro and in vivo efficacy of CRISPR-Cas therapeutics targeting key XDR-TB resistance mutations, deploying distinct modalities including double-strand break (DSB) nucleases (Cas9, Cas12a) for targeted bacterial killing and base editors (CBE/ABE) for resistance allele correction, delivered via lipid nanoparticles (LNPs) or engineered bacteriophages (BxP-1). In vitro, DSB-targeting Cas9 and Cas12a achieved high bactericidal activity against rpoB (S450L) and katG (S315T) mutants, yielding 99.2% and 98.5% kill rates, respectively, while multiplexed Cas9 targeting both loci achieved near-complete clearance (99.9% kill). Conversely, base editors targeting gyrA (D94G) and rrs (A1401G) resensitized resistant strains without direct killing, successfully restoring moxifloxacin and amikacin MICs to 0.25 μg/mL and 1.0 μg/mL. In vivo, the multiplexed rpoB + katG Cas9 therapy demonstrated the highest efficacy with a 3.5 ± 0.2 Δ log₁₀ CFU reduction in lung burden, outperforming the standard XDR-TB small-molecule regimen (3.1 ± 0.3 Δ log₁₀ CFU), with single target DSB and base-editing therapies also yielding substantial reductions (1.4–2.8 Δ log₁₀ CFU). Crucially, all CRISPR-Cas modalities exhibited exceptional microbiome preservation, with Microbiome Sparing Indices ranging from 0.92 to 0.98, compared to a significantly depleted index of 0.45 for the standard antibiotic regimen. Ultimately, these findings demonstrate that CRISPR-Cas therapeutics, particularly multiplexed DSB approaches and targeted base editors, provide highly effective, mutation-specific clearance and resensitization of XDR-TB, representing a promising next-generation paradigm for treating drug-resistant tuberculosis with minimized host collateral damage.

Zitieren

APA

Munir, M., BiBi, A., Ullah, W., Malik, D. M., Mir, D. N. A., Qureshi, S., Siddiqui, M. F., Rafique, M., & Ahmed, W. (2026). CRISPR-CAS THERAPEUTICS AGAINST EXTENSIVELY DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS: OPPORTUNITIES FOR PRECISION ANTIMICROBIAL INTERVENTION. Genetics and Molecular Research. https://doi.org/10.4238/fsb1e572

Vancouver

Munir M, BiBi A, Ullah W, Malik DM, Mir DNA, Qureshi S, et al. CRISPR-CAS THERAPEUTICS AGAINST EXTENSIVELY DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS: OPPORTUNITIES FOR PRECISION ANTIMICROBIAL INTERVENTION. Genetics and Molecular Research. 2026. doi:10.4238/fsb1e572

BibTeX
@article{Munir2026,
  author = {Munir, Muqadas and BiBi, Asma and Ullah, Wajid and Malik, Dr. Minahil and Mir, Dr. Nazia Akber and Qureshi, Sidra and Siddiqui, Maria Fareed and Rafique, Maham and Ahmed, Waneeza},
  title = {CRISPR-CAS THERAPEUTICS AGAINST EXTENSIVELY DRUG-RESISTANT MYCOBACTERIUM TUBERCULOSIS: OPPORTUNITIES FOR PRECISION ANTIMICROBIAL INTERVENTION},
  journal = {Genetics and Molecular Research},
  year = {2026},
  doi = {10.4238/fsb1e572}
}
Kostenlos starten →